Breaking news

Theramir Secures €525,000 To Propel Cancer Therapy To Clinical Phase

In a significant boost to its pioneering cancer treatment research, Theramir has successfully raised €525,000 in a bridge funding round. This capital injection is poised to support the company’s operations through the latter half of 2025, targeting a critical milestone: the initiation of clinical trials for their innovative therapy, EVmiR.

EVmiR, now patented by the European Patent Office, represents a novel approach in cancer treatment. By utilising extracellular vesicles (EVs) to deliver microRNAs (miRNAs) directly into tumours, Theramir aims to target oncoproteins—key regulators of cancer cell growth. This precision method promises fewer side effects compared to traditional treatments such as chemotherapy. The company’s technology has demonstrated efficacy in treating metastatic breast cancer and is now being tested for pancreatic and bladder cancers.

Theramir, co-founded by Marianna Prokopi-Demetriades and Costas Pitsillides in 2016, emerged from a passionate pursuit to find a cure for cancer. Their unique technology capitalises on EVs’ natural ability to transport biological information, essentially turning them into couriers that deliver tumour-suppressive messages via miRNAs. This method requires a detailed genetic profile of the patient to enhance the therapy’s precision and effectiveness, potentially offering prophylactic benefits by identifying genetic markers linked to high-risk conditions.

The latest funding round saw participation from notable investors, including Yannos Palate, a former executive at Eli Lilly, who will join Theramir’s advisory board. His extensive experience in life sciences and pharmaceutical engagement is expected to be instrumental in forging strategic partnerships with major pharmaceutical companies. Other investors include Nicosia-based family office Exerte Partners and finance and corporate lawyer Nancy Erotocritou.

Despite the challenges posed by the limited local life-sciences ecosystem in Cyprus, Theramir has managed to attract significant investor interest, raising €2.5 million in total, including €300,000 in grants. The company’s innovative approach and lower research costs compared to major biotech hubs like Boston or London have contributed to its success.

Looking ahead, Theramir is actively seeking a licensing deal with a major pharmaceutical firm to support the clinical trials, which could span up to seven years. The co-founders are optimistic about expediting the timeline through process efficiencies, projecting a market-ready therapy by 2030. In the interim, they are also exploring new revenue streams, such as using EVmiR to treat chronic malignant wounds through a project named MIRACULOUS, which has secured additional funding.

Anthropic’s Opus 5.5 Arrives With Lower Costs, Faster Performance And Sharper Safety Guardrails

Anthropic on Tuesday unveiled Opus 5.5, its latest flagship model and, by the company’s account, a new state of the art in coding and knowledge work.

Opus remains the top tier in Anthropic’s three-model Claude family, positioned above Sonnet and Haiku, which serve the middle and entry-level segments respectively. The company says the new release not only outperforms the larger Fable model on several benchmarks, but also completed a number of informal tasks that Fable could not finish.

A More Efficient Frontier Model

One of the most notable changes is economic, not just technical. Anthropic says output tokens for Opus 5.5 will be priced at $20 per million, down from $25 for the previous version. Other usage metrics have also declined, and the model is faster to run, reflecting lower compute requirements to serve it.

That matters because model economics are increasingly central to enterprise adoption. In practice, a more capable model is only part of the equation; speed and cost often determine whether it can be deployed at scale across software development, research, customer operations, and internal knowledge workflows.

Sharper Communication, Less Jargon

Anthropic says the update also changes how Opus communicates. The new model is less likely to lean on jargon and more likely to lead with the most important information first. For business users, that is more than a stylistic adjustment. It improves readability, reduces friction in decision-making, and makes AI output easier to use in executive settings where time is scarce and clarity matters.

A Rapid Follow-Up To Opus 5

The launch comes just two months after the debut of Opus 5 on July 24. Anthropic said Sonnet 5.5 and Haiku 5.5, the next models in the lineup, will follow “in the coming weeks,” with similar performance gains expected.

Safety Remains Central To The Release

Anthropic says Opus 5.5 is comparable to Mythos in biology and cybersecurity capabilities, which means the model is subject to the same safeguards as the company’s Fable model. Those restrictions limit the model’s use in areas such as discovering exploits in compiled programs or developing recognizable biological weapons, among other sensitive tasks.

The release is also notable because it is Anthropic’s first since CEO Dario Amodei publicly embraced calls to pace the frontier, a strategy designed to slow the rate of capability gains so alignment and safety measures can catch up. In a recent post, Amodei wrote: “I have become convinced that fully addressing the risks requires even more prudence, not just investing in risk prevention, but pacing the rate of capabilities advancement so that risk prevention has time to keep up.”

Preparing The Next Layer Of Oversight

Anthropic said Opus 5.5 underwent safety training broadly similar to earlier models, including alignment testing and pre-release evaluation by external groups such as METR and Frontier Design. At the same time, the company said it is already building more advanced training and evaluation systems for future releases, including stronger security and monitoring infrastructure.

“As AI becomes more capable, public policy should play a larger role in making sure the systems people rely on are safe,” the company wrote in its announcement. “That capacity takes time to build, and we’ve started to put the infrastructure in place to support it. We expect to share more details on these efforts soon.”

The Future Forbes Realty Global Properties
eCredo
Aretilaw firm
Uol

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter